Annexon Reports Rapid GBS Responses with Tanruprubart in FORWARD Study
BRISBANE, Calif., August 6, 2026 Annexon, Inc. announced encouraging early clinical results from the ongoing FORWARD open-label study, with...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
BRISBANE, Calif., August 6, 2026 Annexon, Inc. announced encouraging early clinical results from the ongoing FORWARD open-label study, with...
MAPLE GROVE, Minn., July 7, 2026 Francis Medical has announced that Orange County Urology Associates (OCUA) has become the...
BEVERLY, Mass., July 7, 2026 Akston Biosciences Corporation has announced encouraging preclinical data demonstrating that its investigational NGF-targeting Ambifect®...
ALAMEDA, Calif., July 7, 2026 Penumbra, Inc., a global leader in thrombectomy technologies, has announced the first patient enrollment...
